EGFR and non-small cell lung carcinoma: AURA-3 is a phase III clinical study designed for the secondary EGFR T790M mutation in advanced NSCLC after first-generation TKI resistance, in which patients treated with osimertinib presented significantly increased ORR (71% vs. 31%), and PFS (10.1 months vs. 4.4 months), compared with those treated with a platinum-based dual drug treatment.